Pfizer Inc. (NYSE:PFE) Shares Bought by Gilbert & Cook Inc.

Gilbert & Cook Inc. raised its holdings in shares of Pfizer Inc. (NYSE:PFE) by 1.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,693 shares of the biopharmaceutical company’s stock after acquiring an additional 450 shares during the period. Gilbert & Cook Inc.’s holdings in Pfizer were worth $682,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of PFE. AQR Capital Management LLC boosted its position in Pfizer by 1.6% during the 2nd quarter. AQR Capital Management LLC now owns 612,429 shares of the biopharmaceutical company’s stock worth $17,068,000 after acquiring an additional 9,435 shares during the period. Quarry LP acquired a new position in Pfizer in the 2nd quarter valued at approximately $31,000. Dana Investment Advisors Inc. raised its position in Pfizer by 9.6% in the second quarter. Dana Investment Advisors Inc. now owns 100,181 shares of the biopharmaceutical company’s stock worth $2,803,000 after purchasing an additional 8,771 shares in the last quarter. Souders Financial Advisors raised its stake in Pfizer by 6.1% during the second quarter. Souders Financial Advisors now owns 8,347 shares of the biopharmaceutical company’s stock worth $234,000 after acquiring an additional 483 shares in the last quarter. Finally, Birmingham Capital Management Co. Inc. AL boosted its position in Pfizer by 0.9% in the second quarter. Birmingham Capital Management Co. Inc. AL now owns 181,763 shares of the biopharmaceutical company’s stock valued at $5,086,000 after buying an additional 1,559 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Guggenheim cut their price target on Pfizer from $35.00 to $33.00 and set a “buy” rating for the company in a report on Wednesday, December 11th. Bank of America reissued a “neutral” rating and set a $29.00 price objective on shares of Pfizer in a research note on Tuesday, December 10th. UBS Group dropped their target price on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a report on Wednesday, January 8th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research report on Wednesday, October 23rd. Finally, Truist Financial reduced their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Trading Up 0.2 %

Pfizer stock traded up $0.05 during trading hours on Thursday, reaching $26.67. The stock had a trading volume of 1,155,444 shares, compared to its average volume of 34,178,785. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The company has a fifty day simple moving average of $26.22 and a 200-day simple moving average of $27.90. The stock has a market cap of $151.16 billion, a PE ratio of 36.04, a PEG ratio of 0.64 and a beta of 0.64. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. The company had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. Pfizer’s revenue was up 31.2% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.17) earnings per share. Analysts forecast that Pfizer Inc. will post 2.94 EPS for the current fiscal year.

Pfizer Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be given a dividend of $0.43 per share. This is a boost from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a yield of 6.45%. The ex-dividend date is Friday, January 24th. Pfizer’s dividend payout ratio (DPR) is 227.03%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.